REDWOOD CITY, Calif.--(BUSINESS WIRE)--Karius®, Inc., a world leader in genomic diagnostics for infectious disease, today announced it has secured $100 million in Series C funding. The round was co-led by Khosla Ventures and new investors 5AM Ventures and Gilde Healthcare. Also investing was new investor Seventure Partners, and existing investors Softbank Vision Fund 2, General Catalyst, HBM Healthcare Investments, Blue Water Life Sciences, Innovation Endeavors, Waycross Ventures, and others..

加利福尼亚州红木市（商业新闻短讯）--传染病基因组诊断领域的全球领导者Karius®公司今天宣布，它已获得一亿美元的C系列资金。科斯拉风险投资公司（Khosla Ventures）、新投资者5AM风险投资公司（new investors 5AM Ventures）和吉尔德医疗集团（Gilde Healthcare）共同领导了这一轮投资。新投资者Seventure Partners和现有投资者Softbank Vision Fund 2、General Catalyst、HBM Healthcare Investments、Blue Water Life Sciences、Innovation Effirations、Waycross Ventures等也进行了投资。

This investment will enable Karius to extend its reach beyond the 400 U.S. hospitals currently using the Karius Test®, an infectious disease diagnostic test that utilizes genomic analysis and artificial intelligence to detect over 1,000 pathogens from a single blood sample. The funding enables Karius to address increasing demand from healthcare providers to expand access to the Karius Test beyond the hospital setting.

这项投资将使Karius能够将其影响力扩展到目前使用Karius Test®的400家美国医院之外，Karius Test®是一种传染病诊断测试，利用基因组分析和人工智能从单个血液样本中检测出1000多种病原体。这笔资金使Karius能够满足医疗保健提供者日益增长的需求，将Karius测试的范围扩大到医院以外。

Additionally, it will support research into the broader health implications of Karius’ microbial cell-free DNA technology beyond infectious diseases..

此外，它将支持研究卡里乌斯的微生物无细胞DNA技术对传染病以外的更广泛健康影响。

“Every minute in the U.S., five cancer patients are admitted to the hospital due to infections—conditions that are often overshadowed by their primary diagnosis but are equally lethal, leading to nearly 1,000 deaths daily,” said Alec Ford, CEO of Karius. “This worrying reality emphasizes a critical and frequently overlooked gap in our healthcare system: the urgent need for faster diagnostic solutions.

Karius首席执行官亚历克·福特（AlecFord）表示：“在美国，每分钟就有五名癌症患者因感染而入院，这些感染通常被他们的初步诊断所掩盖，但同样致命，每天导致近1000人死亡。”。“这一令人担忧的现实强调了我们医疗保健系统中一个关键且经常被忽视的差距：迫切需要更快的诊断解决方案。

At Karius, we confront this challenge head-on. The Karius Test can reduce the time required to identify the cause of infections, as every minute counts for cancer patient survival. This additional $100 million will significantly enhance our capacity to deliver rapid diagnostic testing to more patients, where faster treatment saves more lives and significant healthcare resources.”.

在Karius，我们正面面对这一挑战。Karius测试可以减少确定感染原因所需的时间，因为每一分钟都对癌症患者的生存至关重要。这一额外的一亿美元将大大提高我们为更多患者提供快速诊断测试的能力，更快的治疗可以挽救更多的生命和大量的医疗资源。”

New Board Appointments

新董事会任命

Karius also announced the appointment of three new board members joining recent additions, Dr. Norman Sharpless M.D., former National Cancer Institute Head, and Elizabeth O'Farrell, former Eli Lilly executive:

卡里斯还宣布任命三名新的董事会成员加入最近的新成员，前国家癌症研究所所长诺曼·夏普利斯博士和前礼来高管伊丽莎白·奥法雷尔：

Alex Morgan, M.D., Ph.D., Partner at Khosla Ventures

亚历克斯·摩根，医学博士，博士，科斯拉风险投资公司合伙人

Joep Muijrers, Ph.D., General Partner at Gilde Healthcare

Joep Muijrers博士，Gilde Healthcare普通合伙人

Andrew Booth, Venture Advisor to 5AM Ventures, and CFO of AbCellera Biologics

安德鲁·布斯（AndrewBooth），5AM Ventures的风险顾问，AbCellera Biologics的首席财务官

“Investing in Karius addresses critical gaps in healthcare diagnostics,” stated Alex Morgan, Partner at Khosla Ventures. “Traditional methods can be slow and can contribute to overuse of antibiotics, particularly risky for immunocompromised patients and fueling Antimicrobial Resistance (AMR). Precisely identifying pathogens allows for targeted treatment, minimizing the use of broad-spectrum antibiotics and reducing the risk of AMR proliferation.

科斯拉风险投资公司（Khosla Ventures）合伙人亚历克斯·摩根（Alex Morgan）表示：“投资卡里乌斯（Karius）解决了医疗保健诊断方面的关键差距。”。“传统方法可能速度较慢，可能导致抗生素的过度使用，特别是对免疫功能低下的患者而言，这是一种风险，并会加剧抗菌素耐药性（AMR）。准确识别病原体可以进行靶向治疗，最大程度地减少广谱抗生素的使用，并降低AMR扩散的风险。

This investment aligns with our commitment to advancing technologies for better public health outcomes.”.

这项投资符合我们推进技术以取得更好公共卫生成果的承诺。”

“We are thrilled to partner with Karius and to support the company in its journey to help deliver better care at lower cost to some of the most vulnerable patients out there,” added Joep Muijrers, General Partner at Gilde Healthcare.

Gilde Healthcare的普通合伙人Joep Muijrers补充道：“我们很高兴与Karius合作，并支持该公司以更低的成本为一些最脆弱的患者提供更好的护理。”

“Karius’ strong revenue and growth illustrates how impactful the Karius Test is to clinical care. We are proud to co-lead the company’s Series C as Karius expands into new markets and moves to profitability,” added Andrew Booth, Venture Advisor, at 5AM Ventures.

“Karius强劲的收入和增长说明了Karius测试对临床护理的影响。随着Karius进入新市场并走向盈利，我们很自豪能够共同领导公司的C系列，”风险投资顾问Andrew Booth在上午5点Ventures补充道。

“Over the years, we’ve witnessed firsthand the repeat impact Karius has made on patient management across numerous clinical settings,” added Vali Barsan, M.D., Karius Board Member and investor for SoftBank Investment Advisers. “Alongside our new as well as existing investors, we’re proud to extend our partnership with the Karius team as they continue to scale precision metagenomics for more rapid and definitive diagnostics that enable better patient outcomes.”.

“多年来，我们亲眼目睹了Karius在众多临床环境中对患者管理产生的反复影响，”Karius董事会成员兼软银投资顾问投资者Vali Barsan医学博士补充道。“与我们的新投资者和现有投资者一起，我们很荣幸与Karius团队扩大合作伙伴关系，因为他们将继续扩展精密宏基因组学，以实现更快速和明确的诊断，从而实现更好的患者预后。”

Karius’ Series C financing coincides with the positive results from the PICKUP1 trial, a landmark multi-center study enrolling 257 hospitalized adults with pneumonia and active hematologic malignancies across 10 leading medical centers, including Duke University Health, MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, and University of California, San Francisco Medical Center.

Karius的C系列融资与PICKUP1试验的积极结果相吻合，PICKUP1试验是一项具有里程碑意义的多中心研究，在10个领先的医疗中心招募了257名患有肺炎和活动性血液系统恶性肿瘤的住院成年人，包括杜克大学健康中心，MD安德森癌症中心，纪念斯隆·凯特琳癌症中心和加利福尼亚大学旧金山医学中心。

When added to the standard of care workup, the Karius Test detected 40% (21/52) more infections with a potential to change medical management for 81% (17/21) of these cases, demonstrating a significant additive diagnostic value in patients with blood cancers or bone marrow transplants. This first-of-its-kind study underscores the Karius Test's potential to transform the diagnostic journey and patient care..

当加入标准护理检查时，Karius测试检测到40%（21/52）以上的感染，其中81%（17/21）的病例有可能改变医疗管理，这表明对血癌或骨髓移植患者具有显着的附加诊断价值。这是同类研究中的第一项，强调了Karius测试在改变诊断过程和患者护理方面的潜力。

“We’ve done extensive due diligence, and the value that Karius brings to patients and the healthcare system at large is abundantly clear,” said Isabelle De Cremoux, CEO and Managing Partner of Seventure Partners. “The clinical evidence clearly shows its potential to help more patients. We’re excited to join Karius at such a key strategic time for the company as they grow to support the wider commercialization of the Karius Test.”.

Seventure Partners首席执行官兼管理合伙人伊莎贝尔·德·克雷莫（Isabelle De Cremoux）表示：“我们已经进行了广泛的尽职调查，卡里乌斯（Karius）为患者和整个医疗保健系统带来的价值非常明显。”。“临床证据清楚地表明，它有可能帮助更多患者。我们很高兴在公司成长的关键战略时刻加入Karius，以支持Karius测试的更广泛商业化。”

Learn more about Karius’ solutions for infectious disease diagnostics by visiting kariusdx.com.

访问kariusdx.com了解更多关于Karius传染病诊断解决方案的信息。

About Karius

关于Karius

Karius Inc., a global leader in liquid biopsy for infectious diseases, harnesses metagenomics, next-generation sequencing, and artificial intelligence (AI) to help enhance the precision and speed of pathogen diagnosis. The Karius Test®, used in over 400 healthcare institutions–including 90+ transplant centers and 40+ children’s hospitals across the United States–identifies more than 1,000 pathogens, including viruses, bacteria, fungi, and parasites from a single blood draw typically within a day of sample receipt..

Karius Inc.是传染病液体活检的全球领导者，它利用宏基因组学，下一代测序和人工智能（AI）来帮助提高病原体诊断的准确性和速度。Karius Test®用于400多家医疗机构，包括全美90多家移植中心和40多家儿童医院，通常在收到样本后的一天内，从一次抽血中识别出1000多种病原体，包括病毒、细菌、真菌和寄生虫。

A landmark study in the Journal of Clinical Microbiology found that the Karius Test detected 701 unique microbial taxa across a cohort of 15,000 patients, making it the largest study of its kind, demonstrating the capability of the Karius Test in pathogen identification. The Karius Test also has been incorporated into the diagnostics recommendations in the 2023 Duke-ISCVID Criteria for Infective Endocarditis..

《临床微生物学杂志》（Journal of Clinical Microbiology）上一项具有里程碑意义的研究发现，Karius测试在15000名患者队列中检测到701种独特的微生物类群，这是同类研究中最大的一项研究，证明了Karius测试在病原体鉴定中的能力。Karius试验也已纳入2023年杜克ISCVID感染性心内膜炎标准的诊断建议中。